Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma
1
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background: Minimal residual disease (MRD) is an important prognostic factor for evaluating a deeper treatment response in patients with multiple myeloma (MM). We evaluated the clinical utility of next-generation flow (NGF)-based MRD assessment in a heterogeneous MM patient population. Methods: Patients with suspected morphological remission after or during MM treatment were prospectively enrolled. In total, 108 bone marrow samples from 90 patients were analyzed using NGF-based MRD assessment according to the EuroFlow protocol, and progression-free survival (PFS) was evaluated according to the International Myeloma Working Group response status, cytogenetic risk, and MRD status. Results: The overall MRD-positive rate was 31.5% (34/108 samples), and MRD-positive patients showed a lower PFS than MRD-negative patients (P=0.005). MRD-positive patients showed inferior PFS than MRD-negative in patients with stringent complete remission (sCR)/complete remission (P=0.014) and high-risk cytogenetic abnormalities (P=0.016). MRD was assessed twice in 18 patients with a median interval of 12 months. Sustained MRD negativity was only observed in patients with sustained sCR, and their PFS was superior to that of patients who were not MRD-negative (P=0.035). Conclusions: Clinical application of NGF-based MRD assessment can provide valuable information for predicting disease progression in patients with MM in remission, including those with high-risk cytogenetic abnormalities.
Abstract
Background: Minimal residual disease (MRD) is an important prognostic factor for evaluating a deeper treatment response in patients with multiple myeloma (MM). We evaluated the clinical utility of next-generation flow (NGF)-based MRD assessment in a heterogeneous MM patient population. Methods: Patients with suspected morphological remission after or during MM treatment were prospectively enrolled. In total, 108 bone marrow samples from 90 patients were analyzed using NGF-based MRD assessment according to the EuroFlow protocol, and progression-free survival (PFS) was evaluated according to the International Myeloma Working Group response status, cytogenetic risk, and MRD status. Results: The overall MRD-positive rate was 31.5% (34/108 samples), and MRD-positive patients showed a lower PFS than MRD-negative patients (P=0.005). MRD-positive patients showed inferior PFS than MRD-negative in patients with stringent complete remission (sCR)/complete remission (P=0.014) and high-risk cytogenetic abnormalities (P=0.016). MRD was assessed twice in 18 patients with a median interval of 12 months. Sustained MRD negativity was only observed in patients with sustained sCR, and their PFS was superior to that of patients who were not MRD-negative (P=0.035). Conclusions: Clinical application of NGF-based MRD assessment can provide valuable information for predicting disease progression in patients with MM in remission, including those with high-risk cytogenetic abnormalities.
참고문헌 (17)
- Bal S, "Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma", Br J Haematol, 186, pp.807~819 (2019)
- Oliva S, "Clinical applications and future directions of minimal residual disease testing in multiple myeloma", Front Oncol, 10, pp.1~ (2020)
- Romano A, "Minimal residual disease assessment within the bone marrow of multiple myeloma: a review of caveats, clinical significance and future perspectives", Front Oncol, 9, pp.699~ (2019)
- Zhong Yiming, "Application of Next Generation Sequencing in Laboratory Medicine", Annals of Laboratory Medicine, 41(1), pp.25~43 (2021), 대한진단검사의학회[DOI]
- Kumar S, "International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma", Lancet Oncol, 17, pp.e328~e346 (2016)
- Lahuerta JJ, "Depth of response in multiple myeloma : a pooled analysis of three PETHEMA", GEM clinical trials, 2017, pp.35, 2900~2910
- Mailankody S, "Minimal residual disease in multiple myeloma : bringing the bench to the bedside", Nat Rev Clin Oncol, 12, pp.286~295 (2015)
- 정현애, "Clinical Utility of a Diagnostic Approach to Detect Genetic Abnormalities in Multiple Myeloma: A Single Institution Experience", Annals of Laboratory Medicine, 38(3), pp.196~203 (2018), 대한진단검사의학회[DOI]
- Flores-Montero J, "Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma", Leukemia, 31, pp.2094~2103 (2017)
- Arroz M, "Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting", Cytometry B Clin Cytom, 90, pp.31~39 (2016)
- Perrot A, "Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma", Blood, 132, pp.2456~2464 (2018)
- Kunacheewa C, "Minimal residual disease negativity does not overcome poor prognosis in high-risk multiple myeloma : A single-center retrospective study", Clin Lymphoma Myeloma Leuk, 20, pp.e221~e238 (2020)
- D’Agostino M, "Pursuing a curative approach in multiple myeloma : a review of new therapeutic strategies", Cancers, 11, pp.2015~ (2019)
- Landgren O, "Meeting report : advances in minimal residual disease testing in multiple myeloma 2018", Adv Cell Gene Ther, 2, pp.e26~ (2019)
- Munshi NC, "Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis", JAMA Oncol, 3, pp.28~35 (2017)
- Martínez-López J, "Critical analysis of the stringent complete response in multiple myeloma : contribution of sFLC and bone marrow clonality", Blood, 126, pp.858~862 (2015)
- Cedena MT, "The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements", PLoS One, 15, pp.e0237155~ (2020)